Anthropic Hit $47B ARR. Stripe Stayed Private (While Public)

Hello everyone,

Jose here. I hope your weekend is going well and you are having a phenomenal Sunday! Sending you good energy your way.

You know it's a chaotic week when the biggest story isn't even the public company debut.

• Anthropic hit $47B ARR (yes, annual recurring revenue, not valuation).

• Stripe's IPO was at $105B (biggest fintech debut ever, and founders kept majority control).

• GitHub employees are demanding equity after Microsoft's secondary buyback.

• And five biotech companies just proved you can actually make recurring revenue from drugs, not just one-off blockbusters.

This isn't hype. This is the market fundamentally rewiring how it values companies.

Let's break down what actually changed.

Read time: 5 mins

Check this future Unicorn looking to IPO very soon 👇

Find the Perfect Voice for Your Brand's AI

Consumers can tell the difference. 79% say AI voices should come from real, attributed actors, and 61% say a voice is most memorable when it's exclusively tied to one brand. 

is the only platform that designs, licenses, and captures your brand's AI voice from real, consenting professional talent—never from scraped data. From strategic voice casting and brand calibration to consent-based rights management and studio-grade capture, we handle the entire process end to end. 

BMW, SuperBloom, and Cresta already trust to build their signature AI voice. Get a demo and see how a licensed, brand-owned voice becomes a real asset—not a legal liability.

FRESH NEWS

The real headline: Anthropic, founded 18 months ago by OpenAI refugees, is now doing $47B in annual revenue. That's $47 billion. Not $47 million. Billion.

The details:

• Revenue run rate: $47 billion annually (as of August 2026)

• Customer base: Enterprise AI (Salesforce, Amazon, Google Cloud, Microsoft all using Claude at enterprise scale)

• Pricing: Enterprise contracts = massive ARR

• Profitability: Already cash-flow positive (rare for AI companies)

• Timeline: Seed to $47B ARR in 18 months (fastest SaaS scaling ever, by far)

• Valuation: Last round valued them at $60B (so 1.3x forward revenue — insane multiple for a SaaS company)

Why this is bonkers:

OpenAI is estimated at $80-100B. Anthropic just proved they can hit revenue numbers at half that timeline.

Most SaaS companies take 10+ years to hit $1B ARR. Anthropic hit $47B in 18 months.

The math doesn't make sense. Unless... enterprise AI is literally changing how software gets valued.

Jose's actual take:

This isn't about Anthropic's technology (though it's excellent). This is about the market finally pricing in "AI became an input cost, not a product."

Every enterprise software company now has to pay Anthropic to function (API calls, model inference, fine-tuning). It's the database infrastructure play, but for AI.

Anthropic isn't going to be "a competitor to OpenAI." They're going to be "the infrastructure layer that everyone runs on."

That changes everything about how the market allocates capital next 5 years.

Prediction: Anthropic IPOs at $300B+ valuation within 24 months. Not because of technology. Because of revenue scale.

The headline: Stripe IPO'd at $105B valuation. Biggest fintech public debut ever. Founders (Patrick and John Collison) announced they're buying back shares to take 51%+ stake (keeping company operationally private even while public).

The details:

• IPO valuation: $105B (compare to PayPal at $200B, Square at $100B, Adyen at $150B)

• Founders' move: Announced secondary offering where they're buying company shares to increase their stake to 51%+

• Revenue: ~$3.5B annually (projected)

• Profitability: Profitable quarter (rare for growth companies)

• Investor reaction: Mixed (founders winning = good, loss of founder control narrative = bad for narrative traders)

Why this is wild:

The Collison brothers just invented a new playbook: "Go public for liquidity and credibility, but stay operationally private through founder control."

This is how you get public company resources (debt access, M&A currency, talent recruitment) without public company pressure (quarterly guidance, activist investors, market volatility).

Jose's actual take:

Stripe just broke the IPO playbook. For 20 years, going public meant "shareholders control your company."

Stripe proved: "You can go public and still control your company if you own >50%."

That's the template for every founder-led company going forward. Don't do a traditional IPO. Do a Stripe IPO: get public market access, keep founder control.

Prediction: 30+ companies copy this playbook in next 5 years. Changes the entire IPO market.

The headline: GitHub employees, holding equity from the 2018 founding round, discovered Microsoft is doing a secondary share buyback at 3x lower prices than the acquisition price.

Employees filed suit arguing Microsoft undervalued their shares.

The details:

• Original GitHub acquisition: 2018 at $7.5B valuation

• Secondary buyback price: Implied $2.5B valuation (2/3 lower)

• Employees affected: ~500-1000 early employees with equity

• Lawsuit claim: "Microsoft used information asymmetry to manipulate prices downward"

• Precedent: First time GitHub employees have legally challenged Microsoft post-acquisition

Why this matters:

For years, startup employees took equity thinking "this is my lottery ticket." Companies (especially Apple, Microsoft, Google) have figured out how to recover that equity after acquisition through secondary buybacks at lower valuations.

Employees just realized: "Wait, we got screwed."

Jose's actual take:

This is the start of a bigger reckoning around acquisition equity. Companies are going to face lawsuits from thousands of employees arguing they weren't adequately informed about secondary buyback risk.

Expect new legal protections: "Acquirer cannot do secondary buyback <X months after acquisition" or "Acquirer must offer original price for <Y years."

This changes M&A strategy for every company going forward. Your acquisition target's employee equity just became a legal liability.

The headline: Novo Nordisk, Eli Lilly, Moderna, BioNTech, and Regeneron all just announced they've shifted to subscription-based drug models (chronic condition subscriptions instead of one-time-cure blocs).

The details:

• The shift: Drugs for chronic conditions (diabetes, obesity, autoimmune) now sold as annual subscriptions

• Pricing: $5K-$15K per year per patient (recurring, forever)

• Market: 100M+ chronically ill Americans = $500B+ recurring market

• Profitability: Subscription model = predictable margins

• Timeline: Contracts now include auto-renew clauses

Why this is paradigm-shifting:

For 70 years, pharma made money on one-time blockbuster drugs. Cure you, you stop taking it, we find new customers.

Subscription model = you take it forever, we keep getting paid forever.

It's the SaaS model applied to medicine.

Jose's actual take:

Biotech just figured out what software learned 10 years ago: Recurring revenue is worth 10x more than one-time revenue.

Companies that lock patients into annual contracts (and make them hard to switch) are going to be worth $500B+ in 5 years.

The old pharma model is dying. The new model is "we're a software company, but for medicine."

Expect every major pharma company to have >70% recurring revenue by 2030. That changes their valuations fundamentally.

PREMIUM ONLY

📰Join Founderscrowd Premium

Join Founderscrowd Premium to get:

• Unique investment opportunties

• Our detailed valuation analysis (why this entry point makes sense)

• The specific risks to watch before IPO

• How to structure your position ($25K minimum)

• Real-time alerts when secondary tranches open

• Step-by-step process to invest

Premium members also get first dibs on allocation — the difference between getting in and getting locked out.

$100/month. Cancel anytime. No commitment.

This is where founders and serious investors actually allocate capital.

Join Premium

💬 QUICK HITS: EVERYTHING ELSE THAT SHAPED THE WEEK

Databricks hits $43B valuation 💰 Secondary market valuation doubled in 4 months. Data lakehouse is real. Investor frenzy is real.

Google kills Bard, merges it with Gmail 🔫 Claude integration into Gmail just got serious competition. Google's not messing around.

Hugging Face raises at $13.5B valuation 🤗 Open-source AI model hub is somehow worth billions. Venture has lost its mind (or they're right).

Retool closes $100M Series C at $1B valuation 🏗️ Low-code platform for internal tools just became a unicorn. Everyone's building internal tools instead of shipping product now.

Wiz turns down $23B acquisition from Google 🚫 Security startup said no to acquisition. Founders want $50B+. Ambition inflation or realistic? (Realistic.)

OpenAI's Sora video model goes mainstream 🎬 Text-to-video is now good enough that creative directors are actually concerned about jobs.

Palantir hits $150B market cap 📊 War-profiteering is apparently very profitable. Stock is up 8x since IPO.

Mistral AI closes $600M round at $2B valuation 🇫🇷 European AI company raised at unicorn status. U.S. doesn't have a monopoly anymore.

Amazon kills AWS AI lab, consolidates to Anthropic partnership 🔗 AWS realized building competing AI was stupid. Just pay Anthropic. Smart.

ByteDance secretly hired 500 AI researchers in Austin, Texas 🤫 China's building AI talent in U.S. now. Geopolitics getting weird.

🔮 HERE'S WHAT THIS WEEK ACTUALLY TOLD US

Pattern 1: Revenue scale changes everything. Anthropic hit $47B ARR in 18 months. That's not a story about technology. That's a story about market capitulation. When every enterprise needs your infrastructure, valuation multiples just disappear.

Pattern 2: Founder control is back. Stripe kept control. Collison brothers staying in charge. GitHub employees suing for equity transparency. The "founder-friendly" era is winning. VCs are just funding capital.

Pattern 3: Subscription beats cures. Biotech finally figured out the SaaS model (chronic condition subscriptions). Software spent 20 years learning this. Biotech just compressed it into one announcement cycle.

Pattern 4: Speed beats perfection. Figure AI beat Tesla on robots by moving faster. Not smarter. Not more funded. Faster.

Pattern 5: Geopolitics is reshaping capital allocation. ByteDance building in Austin. Mistral in Europe. U.S. no longer has a monopoly on AI talent. Capital flows to wherever talent + government support meet.

🎯 THE WEEK'S REAL STORY

It's not about each company. It's about the maturation.

Anthropic proved AI infrastructure is a $100B+ category. Stripe proved founders can stay in control while going public. GitHub proved equity transparency matters legally. Biotech proved SaaS models work in medicine. Figure proved robotics is 2027, not 2035.

The market just matured from "Who's going to win the AI war?" to "How do we extract recurring revenue from AI?"

Companies that figured that out (Anthropic, Moderna, Figure) are about to be worth 10-100x more than companies that didn't.

☕ HUNT ACCORDINGLY

Look for revenue scale (not funding amount). Look for recurring revenue. Look for founder control. Look for speed over perfection.

Avoid pure-play bets on technology. Avoid founders who've never kept control. Avoid one-time revenue models.

The next 5 years belong to people who figured out: Scale + subscription + founder control = $100B+ companies.

Jose